Pasithea Therapeutics (KTTA) announced the acceptance of an abstract for a poster prenstation at the Annual Meeting of the American Society for Clinical Oncology, ASCO, taking place May 30 – June 3, 2025, in Chicago, Illinois. The Company will present updated interim clinical data from its ongoing Phase 1 clinical trial of PAS-004 in patients with MAPK pathway driven advanced solid tumors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KTTA: